Nucor earnings beat by $0.08, revenue fell short of estimates
Harvard Bioscience Inc. (NASDAQ:HBIO) stock has plummeted to a 52-week low, trading at $0.6, marking a significant downturn for the company within the biotechnology equipment sector. With a market capitalization of $26.6 million and an EBITDA of $2.44 million for the last twelve months, the company’s financial metrics reflect its current challenges. InvestingPro analysis indicates the stock is currently trading below its Fair Value. This latest price level reflects a stark contrast to its performance over the past year, with the stock experiencing a precipitous 1-year change, down by -85.38%. While technical indicators from InvestingPro suggest the stock is in oversold territory, investors are closely monitoring HBIO as it navigates through a challenging period, with market sentiment evidently bearish given the substantial retreat from higher valuations. Despite current headwinds, analysts expect the company to return to profitability this year, with projected earnings per share of $0.09. The company’s strategic moves and potential market conditions in the coming months will be critical in determining whether HBIO can recover from this low point. Get access to 10+ additional exclusive ProTips and comprehensive analysis with InvestingPro.
In other recent news, Harvard Bioscience reported its fourth-quarter 2024 earnings, with earnings per share (EPS) of $0.06, which exceeded the anticipated $0.05. The company also reported revenue of $24.6 million, surpassing the forecasted $24.15 million. Despite these positive earnings results, the company experienced a 13% year-over-year decline in quarterly revenue and a 16% drop in full-year revenue compared to 2023. Harvard Bioscience’s full-year revenue amounted to $94 million, down from $112 million the previous year. The company has provided guidance for the first quarter of 2025, projecting revenue between $19 million and $21 million, with gross margins expected to range from 56% to 58%. The company plans to refinance its debt facility by June 2025, with interest rates on new debt facilities projected to be between 10-12%. Harvard Bioscience is focusing on new product opportunities in areas such as CAR T therapy and organoid research to drive future growth. Analysts from KeyBanc and The Benchmark Company have shown interest in the company’s new product introductions and the potential impact of NIH funding uncertainties on revenue.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.